Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Wenker

Internal Medicine Erlanger, KY Medical Doctor

NPI 1760472617 CMS profile 1039948

820 Dolwick Dr, Erlanger, KY 41018

Open in the dashboard

General payments

$17,165

137 records reported · program years 2019–2025

Research payments

$22,870

Paid to them · 28 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,827,046 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Matthew Wenker of Erlanger, KY is reported in the CMS Open Payments database as having received $17,165 across 137 general payments and $22,870 in research payments paid to them. Separately, studies naming them as principal investigator received $12,827,046 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,587 15
2025 Research $1,638 8
2024 General $9,367 64
2024 Research $19,770 15
2023 General $3,632 24
2023 Research $1,462 5
2022 General $23 1
2021 General $366 10
2020 General $627 10
2019 General $1,564 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Wenker
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Matthew Wenker were reported at $1,587. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Matthew Wenker Internal Medicine median Middle half National median
2019 $1,564 $159 $48–$570 $163
2020 $627 $119 $33–$402 $114
2021 $366 $135 $37–$521 $132
2022 $23 $141 $42–$496 $149
2023 $3,632 $149 $45–$519 $160
2024 $9,367 $154 $47–$537 $164
2025 $1,587 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $4,395 31 payments
  2. Merck Sharp & Dohme Corporation $3,735 27 payments
  3. Moderna TX, Inc. $3,206 15 payments
  4. Eli Lilly and Company $2,273 16 payments
  5. Vertex Pharmaceuticals Incorporated $1,434 9 payments
  6. Novartis Pharmaceuticals Corporation $505 5 payments
  7. ACADIA Pharmaceuticals Inc $404 5 payments
  8. Teva Pharmaceuticals USA, Inc. $220 5 payments
  9. Corcept Therapeutics $204 3 payments
  10. AbbVie, Inc. $180 2 payments
  11. Other $610 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,413 55 payments
  2. Food and Beverage $4,736 80 payments
  3. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. NUPLAZID $404 5 payments
  2. AUSTEDO $220 5 payments
  3. VRAYLAR $180 2 payments
  4. Repatha $127 4 payments
  5. Auvelity $123 1 payment
  6. ABILIFY MAINTENA $104 6 payments
  7. CAMZYOS $86 2 payments
  8. REXULTI Psychiatry $72 2 payments
  9. REXULTI Psychiatry $63 3 payments
  10. Korlym $30 1 payment
  11. Other $53 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $18,371 2 payments
  2. Corcept Therapeutics $1,638 8 payments
  3. Novavax Inc $1,462 5 payments
  4. Regeneron Pharmaceuticals, Inc. $1,399 13 payments

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record